The annual meeting of the American Headache Society (AHS) is being held in Denver, Colorado from June 9-12. Here’s a look at just some of the wide-ranging research being presented.
Tag Archive for: AbbVie
A patent cliff is looming once again for the biopharma industry, putting some $236 billion in pharmaceutical sales at risk between now and 2030. For context, the top 10 biopharmas in 2021 generated total global sales of $512 billion. In the next eight years, more than 190 drugs will go off-patent for these companies. Of those, 69 are blockbuster drugs.
Johnson & Johnson and AbbVie’s big-selling leukemia drug Imbruvica in combination with standard treatment kept a rare type of non-Hodgkin lymphoma in check for more than two years longer than the standard regimen alone in older patients, according to data presented on Friday.
A late-stage study of two rheumatoid arthritis drugs from Bristol Myers Squibb (BMY.N) and Johnson & Johnson (JNJ.N) showed a significant drop in deaths among hospitalized COVID patients, a U.S. health agency said on Thursday.
AbbVie Submits New Drug Application to U.S. FDA for Investigational ABBV-951 (Foscarbidopa/Foslevodopa) for the Treatment of Advanced Parkinson’s Disease
AbbVie, Advanced Parkinson's disease, Adverse Events, Clinical Trials, Dyskinesia, Motor fluctuations, Neuroscience, New Drug Application Submission, Parkinson's Disease, R&DAbbVie submitted a New Drug Application to the U.S. Food and Drug Administration for ABBV-951 (foscarbidopa/foslevodopa) for the treatment of motor fluctuations in patients with advanced Parkinson’s disease.
